[go: up one dir, main page]

DE69400435D1 - Verwendung von carbamazepine und oxcarbazepine zur behandlung von parkinson und den parkinson-syndromen - Google Patents

Verwendung von carbamazepine und oxcarbazepine zur behandlung von parkinson und den parkinson-syndromen

Info

Publication number
DE69400435D1
DE69400435D1 DE69400435T DE69400435T DE69400435D1 DE 69400435 D1 DE69400435 D1 DE 69400435D1 DE 69400435 T DE69400435 T DE 69400435T DE 69400435 T DE69400435 T DE 69400435T DE 69400435 D1 DE69400435 D1 DE 69400435D1
Authority
DE
Germany
Prior art keywords
parkinson
pct
treatment
oxcarbazepine
carbamazepine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69400435T
Other languages
English (en)
Other versions
DE69400435T2 (de
Inventor
Alain Boireau
Adam Doble
Pierre Dubedat
Erik Louvel
Mireille Meunier
Jean-Marie Miquet
Jean-Marie Stutzmann
Francoise Bordier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Rhone Poulenc Rorer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer SA filed Critical Rhone Poulenc Rorer SA
Application granted granted Critical
Publication of DE69400435D1 publication Critical patent/DE69400435D1/de
Publication of DE69400435T2 publication Critical patent/DE69400435T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
DE69400435T 1993-01-07 1994-01-03 Verwendung von carbamazepine und oxcarbazepine zur behandlung von parkinson und den parkinson-syndromen Expired - Fee Related DE69400435T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9300074A FR2700117B1 (fr) 1993-01-07 1993-01-07 Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
PCT/FR1994/000004 WO1994015610A1 (fr) 1993-01-07 1994-01-03 Application de la carbamazepine et de l'oxcarbazepine dans le traitement de la maladie de parkinson et des syndromes parkinsoniens

Publications (2)

Publication Number Publication Date
DE69400435D1 true DE69400435D1 (de) 1996-10-02
DE69400435T2 DE69400435T2 (de) 1997-03-06

Family

ID=9442862

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69400799T Expired - Lifetime DE69400799T2 (de) 1993-01-07 1994-01-03 Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
DE69400435T Expired - Fee Related DE69400435T2 (de) 1993-01-07 1994-01-03 Verwendung von carbamazepine und oxcarbazepine zur behandlung von parkinson und den parkinson-syndromen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69400799T Expired - Lifetime DE69400799T2 (de) 1993-01-07 1994-01-03 Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen

Country Status (23)

Country Link
US (2) US5658900A (de)
EP (2) EP0678023B1 (de)
JP (2) JP3120153B2 (de)
KR (2) KR100298807B1 (de)
AT (2) ATE141792T1 (de)
AU (3) AU677279B2 (de)
CA (2) CA2153341A1 (de)
CZ (2) CZ284363B6 (de)
DE (2) DE69400799T2 (de)
DK (2) DK0678026T3 (de)
ES (2) ES2092890T3 (de)
FR (1) FR2700117B1 (de)
GR (2) GR3020975T3 (de)
HU (2) HU217136B (de)
IL (3) IL108286A0 (de)
MX (2) MX9307885A (de)
NO (2) NO952310L (de)
PL (2) PL309594A1 (de)
RU (1) RU2221563C2 (de)
SK (2) SK279758B6 (de)
UA (1) UA29464C2 (de)
WO (3) WO1994015607A1 (de)
ZA (3) ZA9426B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6119094A (en) * 1996-02-29 2000-09-12 Electronic Data Systems Corporation Automated system for identifying alternate low-cost travel arrangements
US6417210B1 (en) * 1998-01-09 2002-07-09 Mor-Research Applications Ltd. Treatment of dyskinesias and Parkinson's disease with riluzole and levodopa
JP2002500181A (ja) * 1998-01-09 2002-01-08 モア−リサーチ・アプリケーシヨンズ・リミテツド ジスキネジーの処置
FR2774592B1 (fr) * 1998-02-06 2000-03-17 Rhone Poulenc Rorer Sa Application du 2-amino-6-trifluoromethoxybenzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet
FR2777781B1 (fr) * 1998-04-24 2004-04-09 Rhone Poulenc Rorer Sa Associations riluzole et l-dopa pour le traitement de la maladie de parkinson
FR2787028B1 (fr) 1998-12-15 2002-10-18 Aventis Pharma Sa Utilisation du riluzole dans le traitement des traumatismes acoustiques
US6506378B1 (en) * 1998-12-16 2003-01-14 Arch Development Corporation Vesicular monoamine transporter gene therapy in Parkinson's disease
FR2801793B1 (fr) * 1999-12-01 2003-07-04 Aventis Pharma Sa Association d'une ergoline et de riluzole et son utilisation comme medicament
ES2211373T1 (es) * 2001-02-12 2004-07-16 Teva Pharmaceutical Industries Ltd. Nuevas formas cristalinas de oxcarbazepina y procedimientos para su preparacion.
WO2005000294A1 (en) * 2003-06-06 2005-01-06 Pharmacia Corporation Selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders
WO2005037276A1 (en) * 2003-10-09 2005-04-28 Aventis Pharma S.A. Use of riluzole for the treatment of essential tremor
CA2471666C (en) * 2004-06-18 2009-10-13 Apotex Pharmachem Inc. An improved process for the preparation of oxcarbazepine and related intermediates
WO2007022568A1 (en) 2005-08-25 2007-03-01 Steven Michael Weiss Reducing myocardial damage and the incidence of arrhythmia arising from loss, reduction or interruption in coronary blood flow
US20070248684A1 (en) * 2006-01-31 2007-10-25 Sigal Blau Pharmaceutical formulations of oxcarbazepine and methods for its preparation
WO2007089247A1 (en) * 2006-01-31 2007-08-09 Teva Pharmaceutical Industries Ltd. Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution
GB0603008D0 (en) * 2006-02-14 2006-03-29 Portela & Ca Sa Method
ATE496623T1 (de) * 2006-04-26 2011-02-15 Supernus Pharmaceuticals Inc Oxcarbazepin-zubereitungen für kontrollierte freisetzung mit sigmoidalem freisetzungsprofil
CA2699411A1 (en) * 2007-09-14 2009-03-19 Scil Technology Gmbh Neuroendocrine factors for treatment of degenerative diseases
JP5675650B2 (ja) 2009-01-20 2015-02-25 ロサンゼルス バイオメディカル リサーチ インスティテュート アットハーバー− ユーシーエルエー メディカル センター 向精神薬の働きを向上させるソルビン酸、安息香酸及びその誘導体
WO2011017319A1 (en) * 2009-08-03 2011-02-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of treating disorders associated with protein polymerization
US8809617B2 (en) * 2009-11-05 2014-08-19 The University of Pittsburgh—Of the Commonwealth System of Higher Education Automated high-content live animal drug screening using C. elegans
US9072772B2 (en) 2009-11-05 2015-07-07 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating disorders associated with protein aggregation
WO2014172372A1 (en) 2013-04-15 2014-10-23 Northwestern University Treatment for dopaminergic disorders
JP6958922B2 (ja) 2016-06-13 2021-11-02 シニュークス インターナショナル（タイワン）コーポレイション 安息香酸ナトリウムの共結晶及びその使用
MX2018015463A (es) 2016-06-13 2019-05-27 Syneurx Int Taiwan Corp Co-cristales de benzoato de litio y sus usos.
US11369579B2 (en) 2016-10-24 2022-06-28 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US10336679B2 (en) 2016-10-24 2019-07-02 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
WO2018228692A1 (en) * 2017-06-14 2018-12-20 Birgit Liss Antagonists of cav2.3 r-type calcium channels for the treatment of neurodegenerative diseases
US10322114B2 (en) 2017-07-31 2019-06-18 Above And Beyond Nb, Llc Formulation of a riluzole solution with beta-cyclodextrins
US10098861B1 (en) 2017-10-24 2018-10-16 Syneurx International (Taiwan) Corp. Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof
US11439626B2 (en) 2019-09-20 2022-09-13 Icahn School Of Medicine At Mount Sinai Controlled release formulations of riluzole and their uses
WO2025063698A1 (en) * 2023-09-18 2025-03-27 Aribio Co. Ltd Lamotrigine and rivastigmine combinations for treating neurodegenerative disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2948718A (en) * 1960-08-09 New n-heterocyclic compounds
CH500196A (de) * 1969-03-10 1970-12-15 Ciba Geigy Ag Verfahren zur Herstellung von neuen Azepinderivaten
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US4431641A (en) * 1980-10-17 1984-02-14 Ciba-Geigy Corporation Pharmaceutical compositions having antiepileptic and antineuralgic action
GB8613183D0 (en) * 1986-05-30 1986-07-02 Wellcome Found Triazine salt
FR2619713B1 (fr) * 1987-08-25 1990-08-31 Rhone Poulenc Sante Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement des troubles du sommeil et de la depression
DE4118740A1 (de) * 1991-06-05 1992-12-10 Schering Ag Neue kombinationspraeparate zur behandlung des morbus parkinson
FR2699077B1 (fr) * 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.

Also Published As

Publication number Publication date
CZ284928B6 (cs) 1999-04-14
EP0678023A1 (de) 1995-10-25
ES2092890T3 (es) 1996-12-01
KR960700059A (ko) 1996-01-19
HU217136B (hu) 1999-11-29
US5674885A (en) 1997-10-07
HU9502065D0 (en) 1995-09-28
CZ176595A3 (en) 1995-12-13
FR2700117A1 (fr) 1994-07-08
WO1994015607A1 (fr) 1994-07-21
EP0678023B1 (de) 1996-10-23
CA2153340C (fr) 2002-12-17
NO952309L (no) 1995-06-12
EP0678026A1 (de) 1995-10-25
US5658900A (en) 1997-08-19
AU5818894A (en) 1994-08-15
DE69400435T2 (de) 1997-03-06
MX9307885A (es) 1994-07-29
WO1994015610A1 (fr) 1994-07-21
CZ284363B6 (cs) 1998-11-11
IL108284A (en) 1999-03-12
SK279645B6 (sk) 1999-01-11
HUT72074A (en) 1996-03-28
RU2221563C2 (ru) 2004-01-20
KR960700054A (ko) 1996-01-19
AU684059B2 (en) 1997-12-04
CA2153341A1 (fr) 1994-07-21
IL108286A0 (en) 1994-04-12
CZ176495A3 (en) 1995-12-13
DE69400799T2 (de) 1997-03-13
HU9502063D0 (en) 1995-09-28
SK86795A3 (en) 1995-11-08
HUT72328A (en) 1996-04-29
MX9400287A (es) 1994-07-29
ATE144420T1 (de) 1996-11-15
NO307495B1 (no) 2000-04-17
PL309596A1 (en) 1995-10-30
AU677279B2 (en) 1997-04-17
UA29464C2 (uk) 2000-11-15
CA2153340A1 (fr) 1994-07-21
NO952310D0 (no) 1995-06-12
DE69400799D1 (de) 1996-11-28
IL108284A0 (en) 1994-04-12
SK86695A3 (en) 1996-05-08
GR3020975T3 (en) 1996-12-31
FR2700117B1 (fr) 1995-02-03
DK0678023T3 (da) 1996-11-25
AU5818994A (en) 1994-08-15
ATE141792T1 (de) 1996-09-15
JPH08505379A (ja) 1996-06-11
EP0678026B1 (de) 1996-08-28
JPH08505378A (ja) 1996-06-11
DK0678026T3 (da) 1996-09-16
ZA9426B (en) 1994-08-11
ZA9432B (en) 1994-08-11
ZA9428B (en) 1994-08-11
PL309594A1 (en) 1995-10-30
NO952310L (no) 1995-06-12
GR3021438T3 (en) 1997-01-31
NO952309D0 (no) 1995-06-12
ES2091689T3 (es) 1996-11-01
WO1994015601A1 (fr) 1994-07-21
JP3120153B2 (ja) 2000-12-25
SK279758B6 (sk) 1999-03-12
AU5819094A (en) 1994-08-15
IL108285A0 (en) 1994-04-12
KR100298807B1 (ko) 2001-11-22

Similar Documents

Publication Publication Date Title
ATE141792T1 (de) Verwendung von carbamazepine und oxcarbazepine zur behandlung von parkinson und den parkinson- syndromen
NO952229D0 (no) Anvendelse av karbamazepin og okskarbazepin ved behandling av neurologiske lesjoner relatert til traumatiske skader
DE69507029D1 (de) Pharmazeutische zusammensetzungen enthaltend einen opiat antagonist und calcium salze, ihre verwendung zur behandlung von endorphin-vermittelten krankheiten
ATE232094T1 (de) Verwendung eines 5ht2 rezeptor-antagonisten zur behandlung von schlafapnoe
HUP0001913A2 (hu) Pramipexole alkalmazása állandóan mozgó láb szindróma kezelésére szolgáló gyógyszerkészítmények előállítására
DE69421705D1 (de) Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen
IL108283A0 (en) Use of riluzole for promoting restoration following radiation

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee